Prevalence of amlodipine-related gingival hyperplasia
Prevalence of amlodipine-related gingival hyperplasia
复制标题
DOI：
10.1902/jop.1997.68.7.676
复制
发表时间：
1997-07-01
影响因子：
4.3
通讯作者：
Jorgensen, MG
中科院分区：
文献类型：
--
作者：
Jorgensen, MG
众所周知，钙通道阻滞剂会导致牙龈增生。在过去的几年里，一种新的钙通道阻滞剂氨氯地平的使用频率越来越高。迄今为止，已发表的6例病例表明氨氯地平也可能促进牙龈增生；然而，没有关于这一现象普遍程度的数据报告。本研究的目的是检查一大批服用氨氯地平的患者，并确定牙龈增生的患病率。150例连续服用氨氯地平（5 mg / d） 6个月以上的牙齿患者，自愿接受牙龈增生、轻度增生(
CALCIUM CHANNEL BLOCKERS ARE KNOWN to contribute to gingival hyperplasia. The vast majority of reports discuss patients taking the drug nifedipine, During the past few years a newer calcium channel blocker, amlodipine, has been used with increasing frequency. To date, six cases have been published indicating that amlodipine may also promote gingival hyperplasia; however no data have been reported regarding the prevalence of this phenomenon. The purpose of this study was to examine a large group of patients taking amlodipine and determine the prevalence of gingival hyperplasia. One hundred fifty dentate patients who had been taking amlodipine, 5 mg per day for at least 6 months, volunteered to undergo a screening examination fur gingival hyperplasia, Mild hyperplasia (